CAS 36507-48-9
:2-Propanol, 1-(2-cyclopentylphenoxy)-3-[(1,1-dimethylethyl)amino]-
- (.+-.)-Isopenbutolol
- (.+-.)-Penbutolol
- 1-(2-Cyclopentylphenoxy)-3-[(1,1-dimethylethyl)amino]-2-propanol
- 1-(Terc-Butilamino)-3-(O-Ciclopentilfenoxi)Propan-2-Ol
- 1-(Tert-Butylamino)-3-(O-Cyclopentylphenoxy)Propan-2-Ol
- 1-(Tert-Butylamino)-3-(O-Cyclopentylphenoxy)Propane-2-Ol
- 2-Propanol, 1-(2-cyclopentylphenoxy)-3-((1,1-dimethylethyl)amino)-
- (2S)-1-(tert-butylamino)-3-(2-cyclopentylphenoxy)propan-2-ol
- 2-Propanol, 1-(2-cyclopentylphenoxy)-3-[(1,1-dimethylethyl)amino]-
rac Penbutolol
CAS:Applications A β-adrenoceptor antagonist. Antihypertensive.
References Armstrong, D., et al.: Anal. Chem., 66, 1473 (1994), Kato, M., et al.: J. Pharm. Biomed. Anal., 30, 1845 (2003),Formula:C18H29NO2Color and Shape:Off-WhiteMolecular weight:291.43rac Penbutolol
CAS:Rac Penbutolol is a beta-adrenergic blocker that has been shown to be effective in the treatment of hypertension, angina pectoris, and arrhythmia. Rac Penbutolol is used for the treatment of hypertension and angina pectoris by blocking the effects of catecholamines on the heart and blood vessels. The drug also decreases peripheral vascular resistance, which lowers blood pressure and reduces cardiac workload. Rac Penbutolol has been shown to be effective in treating atrial fibrillation by slowing conduction through the heart. This drug binds to beta-adrenergic receptors in the heart muscle, causing relaxation of the muscle fibers and preventing them from contracting. Rac Penbutolol can be detected in urine samples using monoclonal antibodies, which are used to identify specific proteins or other substances in a sample. The detection time for rac Penbutolol is typically four days after ingestion when it is taken orally with food. Rac Penbut
Formula:C18H29NO2Purity:Min. 95%Molecular weight:291.4 g/mol(±)-Penbutolol
CAS:(±)-Penbutolol ((Rac)-Penbutolol) is the racemic form of Penbutolol. It acts as an orally active β-adrenergic receptor antagonist. (±)-Penbutolol mitigates the tachycardia induced by exercise, reduces the increase in peak expiratory flow rate (PEFR) caused by physical activity, and decreases plasma renin activity (PRA) at rest. The peak plasma concentration of this compound is achieved one hour after oral administration, with a half-life of 4.5 hours, and it is metabolized into active metabolites in the body. This compound is utilized in research related to cardiovascular diseases.Formula:C18H29NO2Color and Shape:SolidMolecular weight:291.43


